Summary:
A phase 3, multi-center, placebo-controlled, randomized, double-blind, 12-week study to evaluate the effect of two doses of AMR101 on fasting serum triglyceride levels in patients with persistent high triglyceride levels (>200mg/dl and <500 mg/dl) despite statin therapy.
Qualified Participants Must:
• Have high triglycerides
•
Currently be taking a statin such as Lipitor, Crestor, or Zocor
•
Be at least 18 years of age
Qualified Participants May Receive:
Study-related medication, study-related physical examinations, study-related laboratory tests, counseling on a healthy diet and lifestyle and compensation for time and travel.